Gonadorelin: reproductive hormone that triggers ovulation and testosterone
A small brain hormone that tells the pituitary to start ovulation in women and testosterone production in men; once sold as the approved drugs Factrel and Lutrepulse.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Gonadorelin (also called GnRH or LHRH) is a synthetic form of gonadotropin-releasing hormone, a small peptide produced naturally by the hypothalamus — the brain region that sits at the top of the body's reproductive hormone chain. By sending a pulsatile signal to the pituitary gland, it prompts the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive ovulation in women and testosterone production in men. It was historically FDA-approved in the United States under the brand names Factrel (for pituitary function testing) and Lutrepulse (for pulsatile pump therapy in hypothalamic amenorrhea), though both commercial products have since been discontinued.
The stored sequence (HWSYGLRPG, residues 2–10) is a fragment of the full decapeptide; the complete endogenous and synthetic form carries an N-terminal pyroglutamate cap (pyroGlu¹) and a C-terminal amide (Gly¹⁰-NH₂), neither of which appears in the stored nine-letter sequence.
History
Gonadotropin-releasing hormone was isolated and sequenced in the early 1970s by the laboratories of Andrew Schally and Roger Guillemin, work that contributed to their sharing the 1977 Nobel Prize in Physiology or Medicine. The full decapeptide sequence — pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ — proved to be the master upstream regulator of reproductive endocrinology. Detection of this peptide across species has been documented in proteomic surveys; Petruzziello and colleagues (2012) identified the GnRH sequence in the neuropeptidome of the tree shrew (Tupaia belangeri), illustrating its evolutionary conservation. In the decades following discovery, synthetic gonadorelin became a clinical tool for both diagnostic assessment and fertility therapy, and extensive veterinary use for livestock reproductive synchronization generated a large body of applied pharmacology literature.
What it does
Gonadorelin acts on pituitary gonadotroph cells to trigger the release of LH and FSH. LH then travels to the gonads — in women it drives ovulation and corpus luteum formation; in men it stimulates Leydig cells to produce testosterone, a process characterized at the receptor level by Riccetti and colleagues (2017). FSH supports follicle development in women and spermatogenesis in men. A critical feature of this mechanism is that it is entirely frequency-dependent: pulsatile exposure maintains pituitary responsiveness, while continuous exposure causes GnRH receptor downregulation and paradoxically suppresses the gonadotropin axis — the same pharmacological principle that underlies GnRH agonist drugs used to suppress the axis in prostate cancer and endometriosis.
Evidence
- Human: Decades of well-characterized use in diagnostic pituitary function testing; historical FDA-approval data for pulsatile pump therapy (Lutrepulse) in hypothalamic amenorrhea; clinical evidence for cryptorchidism treatment in male infants.
- Animal: Extensive. Gonadorelin is widely used in livestock reproductive synchronization protocols; a large body of randomized trial literature exists in dairy cattle, beef heifers, and camelids. Collado and colleagues (2004) characterized how the GnRH antagonist cetrorelix modulates Gαs and Gαi protein subunits and adenylate cyclase activity in rat ovary, breast, and pituitary — illuminating the downstream signaling machinery.
- In vitro: GnRH receptor binding and Gq/PLC/IP3/DAG signaling cascades are well characterized in pituitary and gonadal cell lines.
Known effects
- Pituitary LH/FSH release — Well-established; basis for diagnostic and therapeutic use
- Ovulation induction — Approved historical use (Lutrepulse pump protocol); extensive human and animal evidence
- Testosterone stimulation via LH — Supported by HPG axis pharmacology; characterized in Leydig cell models (Riccetti et al. 2017)
- Testicular function preservation during exogenous testosterone use — Emerging; no RCTs versus placebo in this specific population; protocols are empirical
- Cryptorchidism treatment — Historical clinical use in male infants; clinical trials conducted
Safety signals
Safety data for diagnostic use (single-dose intravenous or subcutaneous administration) is well established from decades of Factrel use. Published adverse effects in clinical contexts include injection site reactions, headache, nausea, and flushing. Anaphylactoid reactions have been documented with repeated diagnostic use. Because pulsatile and continuous administration have opposite effects on the HPG axis, frequency and mode of delivery are pharmacologically critical: continuous exposure suppresses rather than stimulates gonadotropin secretion, as shown in the mechanistic literature on GnRH receptor desensitization. Long-term safety data specific to multi-year pulsatile TRT-adjunct use in men is limited.
Regulatory status
- US: No currently marketed FDA-approved product. Gonadorelin was historically approved as Factrel (Ayerst/Wyeth; pituitary function testing) and Lutrepulse (Ferring; pulsatile pump for hypothalamic amenorrhea); both are discontinued. The FDA flagged gonadorelin for safety review in the 503A compounding context in 2024, narrowing access through compounding pharmacies.
- EU/International: Human prescribing availability varies by jurisdiction. Veterinary use for reproductive synchronization in livestock remains extensive internationally.
- WADA: Prohibited at all times (in and out of competition) under category S2 — peptide hormones, growth factors, related substances and mimetics — covering gonadotropin-releasing hormone and analogs.
Myths and misconceptions
- "Gonadorelin is the same as hCG." Not the same. Human chorionic gonadotropin (hCG) mimics LH and acts directly on Leydig cells in the testes, bypassing the pituitary. Gonadorelin acts upstream on the pituitary to stimulate the body's own LH and FSH release, preserving the full hypothalamic-pituitary-gonadal axis rather than replacing one level of it.
- "Continuous gonadorelin gives a stronger effect than pulsatile dosing." The opposite is true. Continuous GnRH receptor stimulation leads to receptor internalization and desensitization, which suppresses gonadotropin secretion — the same mechanism that GnRH agonists like leuprolide exploit therapeutically to suppress the HPG axis in hormone-sensitive cancers. Only pulsatile delivery maintains stimulatory effect.
- "Gonadorelin is a currently FDA-approved drug." Both US-approved products (Factrel and Lutrepulse) have been discontinued; there is no currently marketed FDA-approved gonadorelin product in the United States.
Mechanism
Gonadorelin (full form: pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂) binds the GnRH receptor (GnRHR), a class A GPCR expressed on pituitary gonadotroph cells. Receptor activation proceeds through Gq-coupled phospholipase C signaling, generating IP₃ and DAG, raising intracellular calcium and activating protein kinase C. This cascade drives synthesis and exocytotic release of LH and FSH. Pulse frequency shapes the LH:FSH output ratio — higher frequency favors LH predominance; lower frequency favors FSH. Released LH then acts at the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) in the gonads: in men, this stimulates Leydig cell testosterone synthesis through early signaling pathways characterized by Riccetti and colleagues (2017); in women, the mid-cycle LH surge triggers ovulation and corpus luteum formation. Collado and colleagues (2004) demonstrated, using the GnRH antagonist cetrorelix, that GnRH signaling modulates both Gαs and Gαi subunit expression and adenylate cyclase activity in ovarian, breast, and pituitary tissue, reflecting the breadth of downstream effector coupling. Continuous GnRHR occupancy bypasses the pulsatile requirement, causing receptor internalization and profound gonadotropin suppression — the principle underlying clinical GnRH agonist therapy for prostate cancer, endometriosis, and central precocious puberty.
Open questions
- No randomized controlled trials specifically compare pulsatile gonadorelin against hCG or placebo for testicular volume and spermatogenesis preservation in men on exogenous testosterone therapy.
- Formal pharmacokinetic-pharmacodynamic modeling of pulsatile gonadorelin in the TRT-adjunct population is absent; protocols in current use are empirical.
- Long-term safety of multi-year continuous pulsatile dosing (beyond the months-to-pregnancy timescale of Lutrepulse protocols) has not been formally studied.
- The regulatory trajectory for 503A compounding access in the United States after the 2024 FDA review remains unresolved.
Related peptides
- Leuprolide — a synthetic GnRH agonist (Lupron/Eligard) that exploits continuous GnRHR stimulation to suppress the HPG axis; the pharmacological inverse of pulsatile gonadorelin stimulation
- Triptorelin — another synthetic GnRH agonist (D-Trp6 substitution; Trelstar/Decapeptyl), FDA-approved for prostate cancer and precocious puberty via the same paradoxical HPG-axis suppression mechanism
- Kisspeptin-54 — the upstream hypothalamic regulator that drives endogenous GnRH pulse release; acts one step above gonadorelin in the reproductive axis
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7737362384796143 | boltz-2 |
| ranking score | 0.7302416563034058 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 1.237 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10603,
sequence = {HWSYGLRPG},
target = {lhcgr},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}